Dyne Therapeutics, Inc.
DYNNasdaqCIK 1818794HealthcareFiscal year ends Dec 31
Reports and events: 102 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-03-2507:39 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-075932 |
| 2024-03-0507:41 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-025408 |
| 2024-03-0507:35 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-025402 |
| 2024-01-0508:02 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-002892 |
| 2024-01-0417:12 ET | 8-K | 8.01 Other events | 0001193125-24-002542 |
| 2024-01-0306:37 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-000991 |
| 2023-10-3007:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-056122 |
| 2023-10-3007:25 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-056121 |
| 2023-08-0307:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-037592 |
| 2023-08-0307:26 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-037585 |
| 2023-05-2516:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000950170-23-024258 |
| 2023-05-1107:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-020847 |
| 2023-05-1107:26 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-020839 |
| 2023-04-0716:15 ET | DEF 14A | Proxy statementPeriod 2023-05-24 | 0000950170-23-012196 |
| 2023-03-1012:50 ET | 8-K | 7.01 Regulation FD disclosure | 0000950170-23-007187 |
| 2023-03-0207:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-005714 |
| 2023-03-0207:21 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-005708 |
| 2023-02-1016:31 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-23-032691 |
| 2022-11-0307:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-021556 |
| 2022-11-0307:26 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-021546 |
| 2022-09-1207:07 ET | 8-K | 8.01 Other events | 0000950170-22-018315 |
| 2022-08-0407:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-014477 |
| 2022-08-0407:25 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-014474 |
| 2022-07-0507:35 ET | 8-K | 8.01 Other events | 0000950170-22-012442 |
| 2022-06-0316:30 ET | 8-K | 5.07 Shareholder vote results | 0000950170-22-011171 |
| 2022-05-0216:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-006866 |
| 2022-05-0216:05 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-006860 |
| 2022-04-2216:15 ET | DEF 14A | Proxy statementPeriod 2022-06-03 | 0000950170-22-006010 |
| 2022-03-1007:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-22-003293 |
| 2022-03-1007:21 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-003290 |
| 2022-03-0307:35 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-22-002731 |
| 2021-12-0318:37 ET | 8-K | 8.01 Other events | 0001193125-21-346916 |
| 2021-11-0407:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-21-002935 |
| 2021-11-0407:26 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0000950170-21-002933 |
| 2021-08-0507:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-041180 |
| 2021-08-0507:25 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-041177 |
| 2021-06-0216:59 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-179973 |
| 2021-05-2616:57 ET | 8-K | 5.07 Shareholder vote results | 0001193125-21-173693 |
| 2021-05-0607:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-024527 |
| 2021-05-0607:26 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-024523 |
| 2021-04-1416:15 ET | DEF 14A | Proxy statementPeriod 2021-05-26 | 0001193125-21-116286 |
| 2021-03-0407:43 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-21-010733 |
| 2021-03-0407:26 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001564590-21-010726 |
| 2021-01-1908:10 ET | 8-K | 2.02 Results of operations | 0001193125-21-010864 |
| 2021-01-1908:08 ET | S-1 | Registration statement | 0001193125-21-010863 |
| 2020-12-0917:28 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-20-313953 |
| 2020-11-0507:46 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001564590-20-050881 |
| 2020-11-0507:30 ET | 10-Q | Quarterly reportPeriod 2020-09-30 | 0001564590-20-050870 |
| 2020-10-0116:41 ET | SC 13D | Ownership report, active investor | 0001193125-20-261377 |
| 2020-09-2116:38 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-20-250237 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 5, 2026, 12:06 ET. Listed shows no prices and gives no investment advice.